JP2018531578A5 - - Google Patents

Download PDF

Info

Publication number
JP2018531578A5
JP2018531578A5 JP2017560329A JP2017560329A JP2018531578A5 JP 2018531578 A5 JP2018531578 A5 JP 2018531578A5 JP 2017560329 A JP2017560329 A JP 2017560329A JP 2017560329 A JP2017560329 A JP 2017560329A JP 2018531578 A5 JP2018531578 A5 JP 2018531578A5
Authority
JP
Japan
Prior art keywords
protein
virus
influenza
influenza virus
attenuated influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017560329A
Other languages
English (en)
Japanese (ja)
Other versions
JP6692835B2 (ja
JP2018531578A (ja
Filing date
Publication date
Priority claimed from RU2015147703A external-priority patent/RU2628690C2/ru
Application filed filed Critical
Publication of JP2018531578A publication Critical patent/JP2018531578A/ja
Publication of JP2018531578A5 publication Critical patent/JP2018531578A5/ja
Application granted granted Critical
Publication of JP6692835B2 publication Critical patent/JP6692835B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017560329A 2015-11-06 2016-11-03 感染性疾患の予防及び/又は処置並びに腫瘍性疾患の処置のための弱毒化インフルエンザベクター Active JP6692835B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2015147703A RU2628690C2 (ru) 2015-11-06 2015-11-06 Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
RU2015147703 2015-11-06
PCT/RU2016/050066 WO2017078577A2 (ru) 2015-11-06 2016-11-03 Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний

Publications (3)

Publication Number Publication Date
JP2018531578A JP2018531578A (ja) 2018-11-01
JP2018531578A5 true JP2018531578A5 (enExample) 2019-10-31
JP6692835B2 JP6692835B2 (ja) 2020-05-13

Family

ID=58662984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017560329A Active JP6692835B2 (ja) 2015-11-06 2016-11-03 感染性疾患の予防及び/又は処置並びに腫瘍性疾患の処置のための弱毒化インフルエンザベクター

Country Status (15)

Country Link
US (1) US10392604B2 (enExample)
EP (1) EP3382010A4 (enExample)
JP (1) JP6692835B2 (enExample)
KR (1) KR102604877B1 (enExample)
CN (1) CN108026515B (enExample)
AU (1) AU2016350939B9 (enExample)
CA (1) CA2991023C (enExample)
CU (1) CU24580B1 (enExample)
IL (1) IL255259B (enExample)
MA (1) MA43314A (enExample)
MX (1) MX380393B (enExample)
RU (1) RU2628690C2 (enExample)
SG (1) SG11201709122VA (enExample)
UA (1) UA125333C2 (enExample)
WO (1) WO2017078577A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3632433B1 (en) * 2017-05-26 2025-12-24 Vladimir Evgenievich Nebolsin Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases
US12178869B2 (en) * 2017-12-22 2024-12-31 Codagenix Inc. Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
RU2020132280A (ru) 2018-03-08 2022-04-11 Кодадженикс Инк. Аттенуированные флавивирусы
JP7320601B2 (ja) 2018-09-11 2023-08-03 上▲海▼市公共▲衛▼生▲臨▼床中心 広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
KR102370100B1 (ko) * 2019-02-15 2022-03-07 아이디바이오 주식회사 이종 인플루엔자 a 바이러스에 대한 면역/치료반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 유전자 전달체 및 치료백신
RU2726106C1 (ru) * 2019-07-18 2020-07-09 федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ гриппа им. А.А. Смородинцева" Минздрава России) Рекомбинантный штамм вируса гриппа A/PR8-NS124-TB10.4-2A-HspX и способ специфической профилактики туберкулеза легких с использованием вакцины мукозального применения на его основе
BR112023004433A2 (pt) * 2020-09-11 2023-04-11 Univ Georgia Ácido nucleico, vetor, segmento genômico viral, vírus, composição farmacêutica, método para induzir ou aumentar uma resposta imune contra o vírus influenza, vírus recombinante, método para induzir uma resposta imune em um sujeito em necessidade e polipeptídeo
WO2022103891A1 (en) * 2020-11-11 2022-05-19 California Institute Of Technology Multivalent carriers and related vaccine compositions
CN113430178B (zh) * 2021-06-21 2022-10-11 武汉大学 一种表达ii型单纯疱疹病毒蛋白的重组流感病毒株及其制备方法与应用
WO2025041889A1 (ko) * 2023-08-24 2025-02-27 성신여자대학교 연구산학협력단 외래 항원을 발현하는 재조합 인플루엔자 바이러스 벡터 및 이를 포함하는 백신 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4837827B2 (ja) * 1998-06-12 2011-12-14 マウント シナイ スクール オブ メディシン 新規なウイルス増殖方法およびそのためのインターフェロン欠損培養基
ES2301241T3 (es) * 1998-06-12 2008-06-16 Mount Sinai School Of Medicine Of The City University Of New York Virus de influenza a atenuados, y composiciones inmunogenicas y formulaciones de vacunas que los contienen.
RU2280690C2 (ru) * 2000-03-02 2006-07-27 Полимун Сайнтифик Иммунбиологише Форшунг Гмбх Рекомбинантные вирусы гриппа а
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
US7709190B2 (en) * 2005-12-02 2010-05-04 Board Of Regents, The University Of Texas System Influenza A virus vaccines and inhibitors
EP2048237A1 (en) * 2007-10-05 2009-04-15 Avir Green Hills Biotechnology Research Development Trade Ag Replication deficient Influenza virus for the expression of heterologous sequences
EP2072058A1 (en) * 2007-12-21 2009-06-24 Avir Green Hills Biotechnology Research Development Trade Ag Modified influenza virus
WO2011014504A1 (en) * 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Recombinant influenza virus vectors and uses thereof
CA2805505C (en) * 2009-07-30 2021-08-03 Mount Sinai School Of Medecine Chimeric influenza viruses having reduced ability to reassort with other influenza viruses and uses thereof
WO2011130652A2 (en) * 2010-04-15 2011-10-20 George Baer Compositions and methods for vaccinating humans and animals against enveloped viruses
WO2011156273A1 (en) * 2010-06-06 2011-12-15 Mount Sinai School Of Medicine Recombinant rna viruses and uses thereof
CN103282375B (zh) * 2010-12-02 2017-01-11 比奥诺尔免疫有限公司 肽支架设计
EP2708552A1 (en) * 2012-09-12 2014-03-19 Medizinische Universität Wien Influenza virus

Similar Documents

Publication Publication Date Title
RU2015147703A (ru) Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
Elkashif et al. Adenoviral vector‐based platforms for developing effective vaccines to combat respiratory viral infections
Wang et al. Protective efficacy of the conserved NP, PB1, and M1 proteins as immunogens in DNA-and vaccinia virus-based universal influenza A virus vaccines in mice
JP2019537424A5 (enExample)
Ibañez et al. M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A
RU2014117068A (ru) Вакцина на основе рекомбинантных наночастиц f из rsv против респираторно-синцитиального вируса
JP2013518052A5 (enExample)
Bolduc et al. The quest for a nanoparticle-based vaccine inducing broad protection to influenza viruses
TW202430206A (zh) 組合疫苗
US20230210980A1 (en) Chimeric adenoviral vectors
Kopecky-Bromberg et al. Recombinant vectors as influenza vaccines
Kesik-Brodacka et al. A universal flu vaccine
Lim et al. RNA-dependent assembly of chimeric antigen nanoparticles as an efficient H5N1 pre-pandemic vaccine platform
JP7602457B2 (ja) ペプチド核酸を基盤としたアジュバント
Kim et al. Generation of VHSV replicon particles carrying transmembrane and C-terminal cytoplasmic region-deleted G gene (rVHSV-GΔTM) and comparison of vaccine efficacy with G gene-deleted VHSV (rVHSV-ΔG)
Geeraedts et al. Effect of viral membrane fusion activity on antibody induction by influenza H5N1 whole inactivated virus vaccine
Chang et al. A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus
JP2015527885A (ja) インフルエンザウイルスの亜型又は株に対するワクチン構築物におけるポックスウイルスエレメントについての組成物、方法及び使用
EP4284814A2 (en) Chimeric adenoviral vectors
Attaran et al. Immunogenicity and protective efficacy of recombinant M2e. Hsp70c (Hsp70359–610) fusion protein against influenza virus infection in mice
US20250049912A1 (en) Multicistronic Vaccine and Methods for Producing and Using the Same
RU2016111907A (ru) Аттенуированный гриппозный вектор и мукозальная универсальная гриппозная вакцина на его основе
Ashraf et al. COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform. Vaccines 2021, 9, 171
Fusheng Targeting COVID-19, MERS, and SARS with a Universal Vaccine Strategy
Siddoway Universal room-temperature stable influenza A nanovaccine